BIOCRYST PHARMACEUTICALS, INC.: operating income or loss
Operating income or loss for BIOCRYST PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BIOCRYST PHARMACEUTICALS, INC. financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 340,989,000 | USD | 2026-02-26 | 10-K · 0001628280-26-012240 |
| 2024-01-01 | 2024-12-31 | -2,543,000 | USD | 2026-02-26 | 10-K · 0001628280-26-012240 |
| 2023-01-01 | 2023-12-31 | -103,709,000 | USD | 2026-02-26 | 10-K · 0001628280-26-012240 |
| 2022-01-01 | 2022-12-31 | -148,435,000 | USD | 2025-02-25 | 10-K · 0001628280-25-007715 |
| 2021-01-01 | 2021-12-31 | -177,720,000 | USD | 2024-02-27 | 10-K · 0001628280-24-007205 |
| 2020-01-01 | 2020-12-31 | -174,757,000 | USD | 2023-02-27 | 10-K · 0001628280-23-005259 |
| 2019-01-01 | 2019-12-31 | -99,455,000 | USD | 2022-02-28 | 10-K · 0001171843-22-001460 |
| 2018-01-01 | 2018-12-31 | -94,220,000 | USD | 2021-03-01 | 10-K · 0001171843-21-001411 |
| 2017-01-01 | 2017-12-31 | -57,411,000 | USD | 2020-03-13 | 10-K · 0001171843-20-001710 |
| 2016-01-01 | 2016-12-31 | -48,607,000 | USD | 2019-03-14 | 10-K · 0001171843-19-001727 |
| 2015-01-01 | 2015-12-31 | -39,444,000 | USD | 2018-03-12 | 10-K · 0001171843-18-001855 |
| 2014-01-01 | 2014-12-31 | -45,771,000 | USD | 2017-02-27 | 10-K · 0001171843-17-001159 |
| 2013-01-01 | 2013-12-31 | -30,717,000 | USD | 2016-02-26 | 10-K · 0001171843-16-008207 |
| 2012-01-01 | 2012-12-31 | -33,888,000 | USD | 2015-03-02 | 10-K · 0001171843-15-001186 |
| 2011-01-01 | 2011-12-31 | -49,587,000 | USD | 2014-03-10 | 10-K · 0001193125-14-091609 |
| 2010-01-01 | 2010-12-31 | -34,357,000 | USD | 2013-03-11 | 10-K · 0001193125-13-100999 |
| 2009-01-01 | 2009-12-31 | -13,737,000 | USD | 2012-03-06 | 10-K · 0001193125-12-098926 |
Related financial histories
- BIOCRYST PHARMACEUTICALS, INC.: total assets
- BIOCRYST PHARMACEUTICALS, INC.: total liabilities
- BIOCRYST PHARMACEUTICALS, INC.: stockholders equity
- BIOCRYST PHARMACEUTICALS, INC.: cash and cash equivalents
- BIOCRYST PHARMACEUTICALS, INC.: net income or loss
- BIOCRYST PHARMACEUTICALS, INC.: operating cash flow
- BIOCRYST PHARMACEUTICALS, INC.: capital expenditure payments
- BIOCRYST PHARMACEUTICALS, INC.: revenue
- BIOCRYST PHARMACEUTICALS, INC.: financing cash flow
- BIOCRYST PHARMACEUTICALS, INC.: investing cash flow
- BIOCRYST PHARMACEUTICALS, INC.: retained earnings or deficit
- BIOCRYST PHARMACEUTICALS, INC.: basic weighted-average shares
- BIOCRYST PHARMACEUTICALS, INC.: diluted weighted-average shares
- BIOCRYST PHARMACEUTICALS, INC.: basic earnings per share
- BIOCRYST PHARMACEUTICALS, INC.: diluted earnings per share
- BIOCRYST PHARMACEUTICALS, INC.: income tax expense or benefit
- BIOCRYST PHARMACEUTICALS, INC.: net property, plant and equipment
- BIOCRYST PHARMACEUTICALS, INC.: share-based compensation expense
- BIOCRYST PHARMACEUTICALS, INC.: current assets
- BIOCRYST PHARMACEUTICALS, INC.: interest expense
- BIOCRYST PHARMACEUTICALS, INC.: current liabilities
- BIOCRYST PHARMACEUTICALS, INC.: current accounts payable
- BIOCRYST PHARMACEUTICALS, INC.: net current accounts receivable
- BIOCRYST PHARMACEUTICALS, INC.: common-stock repurchase payments
- BIOCRYST PHARMACEUTICALS, INC.: net inventory
- BIOCRYST PHARMACEUTICALS, INC.: selling, general and administrative expense
- BIOCRYST PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- BIOCRYST PHARMACEUTICALS, INC. / CIK 0000882796
- Captured
- 2026-09-20T05:02:04.268Z
- SEC response SHA-256
64fec42b290a9661564adfbe60f6de7df3ea9fe9bff3ac7d73b79819a05c52a5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000882796.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))